UW has begun treating patients with donanemab, a new Alzheimer's medication that may slow cognitive decline in people with early-stage disease.
The University of Wisconsin (UW) has added the Alzheimer's drug donanemab to its clinical trials, marking a significant step in the fight against the disease. Donanemab, developed by Eli Lilly, targets amyloid plaques in the brain, which are believed to be a key factor in Alzheimer's progression. The drug has shown promising results in early trials, slowing cognitive decline in patients with early-stage Alzheimer's. UW's inclusion of donanemab in its research portfolio is part of a broader effort to find effective treatments and ultimately a cure for Alzheimer's, a disease that affects millions of people worldwide. The trials at UW will help gather more data on the drug's efficacy and safety, contributing to the global effort to combat this debilitating condition.
Humor & Quirks
Fri, April 25, 2025
